| |
Wednesday, February 28, 2024 | 11am ET / 8am PTWhile oral minitablets can offer several advantages in pharmaceutical applications, manufacturing them can be a complex challenge. Join industry experts for a discussion on the intricate journey of drug development, with a look at how minitablets have redefined formulation strategies, efficacy, patient-centric solutions, options for lifecycle management, and more. Sign up now!
|
|
| By Angus Liu The T-cell therapy treatment class, which has transformed the treatment of certain blood cancers, has now reached the solid tumor field thanks to an FDA approval for a first-of-its-kind immunotherapy developed by Iovance Biotherapeutics. |
|
|
|
By Andrea Park More than a year after laying out a plan to divest its patient monitoring and respiratory interventions businesses—sparking months of speculation over potential buyers—Medtronic is reworking the reorganization. |
By Fraiser Kansteiner While Johnson & Johnson’s consumer health spinoff Kenvue prepares to move into a new headquarters in Summit, New Jersey, it appears some staffers won’t be joining the company in the transition. |
By Nick Paul Taylor The dominoes keep falling at Gilead. One week after reporting deaths in blood cancer patients, the Big Biotech has paused enrollment of magrolimab solid tumor trials after the FDA requested a partial clinical hold on the anti-CD47 monoclonal antibody. |
By Angus Liu A Novartis subsidiary handling old products in India has become the target of a strategic review as the Swiss pharma focuses its efforts on newer medicines. |
By Nick Paul Taylor Sanofi’s HIMALAYA adventure has ended in failure, dealing another blow to its RIPK1 collaboration with Denali Therapeutics. |
By Helen Floersh NodThera’s lead clinical-stage drug for Parkinson’s is almost as effective at inducing weight loss as Novo Nordisk’s blockbuster GLP-1 receptor agonist Wegovy, new data shows. |
By Max Bayer Rapt Therapeutics is reeling from an “unfortunate and unexpected” clinical hold after a patient in a phase 2 immunology trial experienced liver failure that may be related to the study drug. |
By Nick Paul Taylor Daiichi Sankyo is in trouble with the U.K.’s Prescription Medicines Code of Practice Authority yet again. But, while the firm was found to have brought discredit upon the industry, it went down swinging in a response that called out the “somewhat malicious and defamatory” wording of a series of anonymous complaints. |
By Joseph Keenan A month after unveiling plans to build a production facility in the United Arab Emirates, San Diego-based manufacturer National Resilience said it will spend $225 million to upgrade its Cincinnati facility and expand its rapid transfer port in North Carolina. |
Fierce podcastsDon’t miss an episode |
| | This week on "Podnosis," Estelle Monod, who leads the global buildings segment at Schneider Electric, sits down with Fierce Healthcare's Anastassia Gliadkovskaya to talk about the sustainability needs of the healthcare sector and ways to address them. |
|
|---|
|
|
|
March 18-20, 2024 | Savannah, GA The Fierce TMF Summit is the must-attend event for clinical document management professionals to learn, network and connect. Gain invaluable insights from unique case studies, panels, and workshops, and access the best networking the industry has to offer. Register now and SAVE $300 until February 23 to take your TMF to the next level. Sign Up Today!
|
|
| WhitepaperSupercharge Your Field Deployment in 2024 with Engaging, Clinically-Oriented and Influential FRMs, MSLs, NAMs and CNEs. Krista Pinto, President, Field Deployment, EVERSANA |
| Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
